Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Real-World Treatment Patterns & Characteristics of Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Analysis of US Claims (2017-2024)

John M. Burke, Ziqi Zhou, Cynthia Gutierrez, Anran Shao, Marley Boyd, Sina Noshad, Andriana Hohlbauch, Nicholas Liu, Karen Repetny, Michelle Fanale, Betsy Mitchell, Tycel Phillips

Blood (2024) 144 (Supplement 1): 7810.

https://doi.org/10.1182/blood-2024-203554

Published: 2024

Journal Articles

A Retrospective Analysis of US Commercial and Medicare Closed-Claims Databases to Evaluate Real-World Characteristics and Treatment Patterns of Patients with Diffuse Large B-Cell Lymphoma (2017-2023)

Tycel Phillips, Ziqi Zhou, Cynthia Gutierrez, Anran Shao, Marley Boyd, Sina Noshad, Andriana Hohlbauch, Nicholas Liu, Karen Repetny, Michelle Fanale, Betsy Mitchell, John M. Burke

Blood (2024) 144 (Supplement 1): 7809.

https://doi.org/10.1182/blood-2024-203380

Published: 2024

Journal Articles

Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

Blood (2024) 144 (Supplement 1): 4489.

https://doi.org/10.1182/blood-2024-200914

Published: 2024

Journal Articles

Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

Blood (2024) 144 (Supplement 1): 4483.

https://doi.org/10.1182/blood-2024-200836

Published: 2024

Journal Articles

A Systematic Literature Review of Clinical Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated in the Third-Line or Later Setting

Sarah Bandy, Amy Wu, Daniel Gratie, Ruslan Horblyuk, Karen Repetny, Michelle Fanale, Betsy Mitchell, Nicholas Liu

Blood (2024) 144 (Supplement 1): 6443.

https://doi.org/10.1182/blood-2024-203238

Published: 2024

Journal Articles

Durability of Complete Responses in Patients from the ECHELON-3 Study

Blood (2024) 144 (Supplement 1): 3101.

https://doi.org/10.1182/blood-2024-194158

Published: 2024

Journal Articles

Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation

Mani Akhtari, Sarah A. Milgrom, Chelsea C. Pinnix, Jay P. Reddy, Wenli Dong, Grace L. Smith, Osama Mawlawi, Zeinab Abou Yehia, Jillian Gunther, Eleanor M. Osborne, Therese Y. Andraos, Christine F. Wogan, Eric Rohren, Naveen Garg, Hubert Chuang, Joseph D. Khoury, Yasuhiro Oki, Michelle Fanale, Bouthaina S. Dabaja

Blood (2018) 131 (1): 84–94.

https://doi.org/10.1182/blood-2017-04-773838

Published: 2018

Journal Articles

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma

Barbara Pro, Ranjana Advani, Pauline Brice, Nancy L. Bartlett, Joseph D. Rosenblatt, Tim Illidge, Jeffrey Matous, Radhakrishnan Ramchandren, Michelle Fanale, Joseph M. Connors, Keenan Fenton, Dirk Huebner, Juan M. Pinelli, Dana A. Kennedy, Andrei Shustov

Blood (2017) 130 (25): 2709–2717.

https://doi.org/10.1182/blood-2017-05-780049

Published: 2017

Includes: Supplemental data

Journal Articles

Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma

Joseph M. Connors, Stephen M. Ansell, Michelle Fanale, Steven I. Park, Anas Younes

Blood (2017) 130 (11): 1375–1377.

https://doi.org/10.1182/blood-2017-05-784678

Published: 2017

Journal Articles

New insights into NLPHL transformation

Michelle Fanale

Blood (2016) 127 (16): 1946–1947.

https://doi.org/10.1182/blood-2016-03-699108

Published: 2016

Journal Articles

Sequence Level Analysis of Hodgkin Lymphoma Clonotypes Detected in Peripheral Blood Using a Next-Generation Sequencing Approach

Yasuhiro Oki, MD, Sattva S. Neelapu, Michelle Fanale, Larry W. Kwak, MD PhD, Luis Fayad, MD, Maria Alma Rodriguez, Michael Wallace, Mark Klinger, Victoria Carlton, Katherine A Kong, Malek Faham, Anas Younes

Blood (2014) 124 (21): 1610.

https://doi.org/10.1182/blood.V124.21.1610.1610

Published: 2014

Journal Articles

SUV max on Pre-Treatment FDG PET Scan Is Not Predictive of Outcome in Follicular Lymphoma after R-CHOP Threapy

Blood (2014) 124 (21): 1629.

https://doi.org/10.1182/blood.V124.21.1629.1629

Published: 2014

Journal Articles

Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma

Kieron Dunleavy, MD, Michelle Fanale, MD, Ann LaCasce, MD, Ariela Noy, Paolo Caimi, MD, Samir Parekh, MD, John W Hayslip, MD, Deepa Jagadeesh, MD MPH, Raymond S Lord, Mary J Lechowicz, MD, Rakesh Gaur, MD, Andrea Lucas, RN, Louis M Staudt, MD PhD, Seth M. Steinberg, PhD, Brad Kahl, MD, Jonathan W. Friedberg, MD, Richard F Little, MPH, MD, Nancy L Bartlett, MD, Wyndham H Wilson, MD PhD

Blood (2014) 124 (21): 395.

https://doi.org/10.1182/blood.V124.21.395.395

Published: 2014

Journal Articles

A novel prognostic scoring system for NLPHL

Michelle Fanale

Blood (2013) 122 (26): 4154–4155.

https://doi.org/10.1182/blood-2013-11-533109

Published: 2013

Journal Articles

Significant Activity Of The mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat In Heavily Pretreated Refractory Hodgkin Lymphoma Patients

Filip Janku, MD, PhD, Ignacio Garrido-Laguna, MD, Vivianne Velez-Bravo, Gerald S. Falchook, MD, Vivek Subbiah, MD, David S. Hong, MD, Yasuhiro Oki, MD, Jason R. Westin, MD, Cesar A. Nunez, M.D., Luis E Fayad, Larry W. Kwak, MD, PhD, Elizabeth J Shpall, MD, Jennifer J. Wheler, MD, Winnie Liang, PhD, Bodour Salhia, PhD, Funda Meric-Bernstam, MD, Razelle Kurzrock, Michelle Fanale, MD

Blood (2013) 122 (21): 3048.

https://doi.org/10.1182/blood.V122.21.3048.3048

Published: 2013

Journal Articles

R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL

Yasuhiro Oki, MD, Jason R. Westin, MD, Nathan Fowler, MD, Sattva Neelapu, MD, F.B. Hagemeister, MD, Peter McLaughlin, MD, Larry W. Kwak, MD, PhD, Jorge Enrique Romaguera, Michelle Fanale, MD, Anas Younes, MD, Maria A. Rodriguez, MD, Robert Z. Orlowski, MD, PhD, Michael Wang, M.D., Souzanne T Ouzounian, Felipe Samaniego, M.D., Luis Fayad, MD

Blood (2012) 120 (21): 3707.

https://doi.org/10.1182/blood.V120.21.3707.3707

Published: 2012

Journal Articles

Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma

Jason R. Westin, MD, Fuliang Chu, PhD, Luis E Fayad, MD, Larry W Kwak, MD, PhD, Nathan H Fowler, MD, Jorge E Romaguera, MD, F.B. Hagemeister, MD, Michelle Fanale, MD, Felipe Samaniego, M.D., Rochelle Allen, RN, Lei Feng, Ph.D, Veerabhadran Baladandayuthapani, PhD, Rinat Rotem-Yehudar, PhD, Sattva Neelapu, MD

Blood (2012) 120 (21): 793.

https://doi.org/10.1182/blood.V120.21.793.793

Published: 2012

Journal Articles

TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas

Jinsheng Weng, Seema Rawal, Fuliang Chu, Hyun Jun Park, Rakesh Sharma, David A. Delgado, Luis Fayad, Michelle Fanale, Jorge Romaguera, Amber Luong, Larry W. Kwak, Sattva S. Neelapu

Blood (2012) 120 (8): 1613–1623.

https://doi.org/10.1182/blood-2011-09-382838

Published: 2012

Includes: Supplemental data

Journal Articles

Experience with obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma

Yasuhiro Oki, Amanda Copeland, Fredrick Hagemeister, Luis E. Fayad, Michelle Fanale, Jorge Romaguera, Anas Younes

Blood (2012) 119 (9): 2171–2172.

https://doi.org/10.1182/blood-2011-11-391037

Published: 2012

Journal Articles

Multi-Trial Safety Evaluation of the Fully Antagonistic Human Anti-CD40 Monoclonal Antibody Lucatumumab (HCD122) in Patients with Relapsed or Refractory B-Cell Malignancies,

Michelle Fanale, MD, William I Bensinger, MD, John C. Byrd, MD, Brett Ewald, PhD, Daniel Carreon, PhD, Johan Baeck, MD, Arnold S. Freedman, MD

Blood (2011) 118 (21): 3702.

https://doi.org/10.1182/blood.V118.21.3702.3702

Published: 2011

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Real-World Treatment Patterns & Characteristics of Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Analysis of US Claims (2017-2024)

A Retrospective Analysis of US Commercial and Medicare Closed-Claims Databases to Evaluate Real-World Characteristics and Treatment Patterns of Patients with Diffuse Large B-Cell Lymphoma (2017-2023)

Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

A Systematic Literature Review of Clinical Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated in the Third-Line or Later Setting

Durability of Complete Responses in Patients from the ECHELON-3 Study

Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma

Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma

New insights into NLPHL transformation

Sequence Level Analysis of Hodgkin Lymphoma Clonotypes Detected in Peripheral Blood Using a Next-Generation Sequencing Approach

SUV max on Pre-Treatment FDG PET Scan Is Not Predictive of Outcome in Follicular Lymphoma after R-CHOP Threapy

Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma

A novel prognostic scoring system for NLPHL

Significant Activity Of The mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat In Heavily Pretreated Refractory Hodgkin Lymphoma Patients

R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL

Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma

TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas

Experience with obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma

Multi-Trial Safety Evaluation of the Fully Antagonistic Human Anti-CD40 Monoclonal Antibody Lucatumumab (HCD122) in Patients with Relapsed or Refractory B-Cell Malignancies,

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only